Goldman Sachs’s BioSpecifics Technologies Corp. BSTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-24,884
| Closed | -$1.31M | – | 5855 |
|
|
2020
Q3 | $1.31M | Sell |
24,884
-4,264
| -15% | -$263K | ﹤0.01% | 3883 |
|
|
2020
Q2 | $1.79M | Sell |
29,148
-101,690
| -78% | -$5.88M | ﹤0.01% | 3537 |
|
|
2020
Q1 | $7.4M | Sell |
130,838
-4,961
| -4% | -$283K | ﹤0.01% | 2326 |
|
|
2019
Q4 | $7.73M | Sell |
135,799
-14,737
| -10% | -$781K | ﹤0.01% | 2627 |
|
|
2019
Q3 | $8.06M | Sell |
150,536
-21,123
| -12% | -$1.23M | ﹤0.01% | 2490 |
|
|
2019
Q2 | $10.3M | Buy |
171,659
+9,027
| +6% | +$568K | ﹤0.01% | 2339 |
|
|
2019
Q1 | $10.1M | Sell |
162,632
-29,691
| -15% | -$1.96M | ﹤0.01% | 2402 |
|
|
2018
Q4 | $11.7M | Buy |
192,323
+96,592
| +101% | +$5.77M | ﹤0.01% | 2235 |
|
|
2018
Q3 | $5.6M | Buy |
95,731
+327
| +0.3% | +$16.7K | ﹤0.01% | 2901 |
|
|
2018
Q2 | $4.28M | Sell |
95,404
-11,718
| -11% | -$504K | ﹤0.01% | 3063 |
|
|
2018
Q1 | $4.75M | Buy |
107,122
+576
| +0.5% | +$24.2K | ﹤0.01% | 2933 |
|
|
2017
Q4 | $4.62M | Buy |
106,546
+882
| +0.8% | +$39.6K | ﹤0.01% | 3071 |
|
|
2017
Q3 | $4.92M | Sell |
105,664
-7,230
| -6% | -$346K | ﹤0.01% | 3162 |
|
|
2017
Q2 | $5.59M | Buy |
112,894
+54,777
| +94% | +$2.87M | ﹤0.01% | 2965 |
|
|
2017
Q1 | $3.19M | Buy |
58,117
+4,297
| +8% | +$227K | ﹤0.01% | 3323 |
|
|
2016
Q4 | $3M | Buy |
53,820
+9,158
| +21% | +$440K | ﹤0.01% | 3479 |
|
|
2016
Q3 | $2.04M | Buy |
44,662
+8,190
| +22% | +$329K | ﹤0.01% | 3814 |
|
|
2016
Q2 | $1.46M | Buy |
36,472
+2,544
| +7% | +$93.2K | ﹤0.01% | 3876 |
|
|
2016
Q1 | $1.18M | Sell |
33,928
-156
| -0.5% | -$5.72K | ﹤0.01% | 3955 |
|
|
2015
Q4 | $1.47M | Buy |
34,084
+163
| +0.5% | +$8.17K | ﹤0.01% | 3923 |
|
|
2015
Q3 | $1.48M | Buy |
33,921
+49
| +0.1% | +$2.64K | ﹤0.01% | 4098 |
|
|
2015
Q2 | $1.75M | Hold |
33,872
| – | – | ﹤0.01% | 3977 |
|
|
2015
Q1 | $1.33M | Buy |
33,872
+4,114
| +14% | +$161K | ﹤0.01% | 4196 |
|
|
2014
Q4 | $1.15M | Buy |
29,758
+19,250
| +183% | +$734K | ﹤0.01% | 4411 |
|
|
2014
Q3 | $371K | Buy |
+10,508
| New | +$309K | ﹤0.01% | 5560 |
|
|
2013
Q4 | – | Sell |
-16,933
| Closed | -$330K | – | 6859 |
|
|
2013
Q3 | $330K | Sell |
16,933
-1,560
| -8% | -$27.6K | ﹤0.01% | 5495 |
|
|
2013
Q2 | $288K | Buy |
+18,493
| New | +$298K | ﹤0.01% | 5347 |
|
Other funds holding BSTC
Goldman Sachs's BSTC Position: Q4 2020 in Review
Goldman Sachs sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2020, closing a stake of 24,884 shares — an estimated $1.31M sold.
Goldman Sachs first reported a position in BSTC in Q2 2013 and held it in 27 quarters. The position peaked at $11.7M in Q4 2018. 1 fund tracked by Wall St. Rank holds BSTC as of Q4 2020.
- Goldman Sachs reported no remaining BioSpecifics Technologies Corp. position as of Q4 2020 after selling out during the quarter.
- Goldman Sachs sold 24,884 BioSpecifics Technologies Corp. shares in Q4 2020, an estimated $1.31M.
- Goldman Sachs first reported a position in BioSpecifics Technologies Corp. in Q2 2013 and held it in 27 quarters.
- Goldman Sachs's BioSpecifics Technologies Corp. position peaked at $11.7M in Q4 2018.
- 1 fund tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2020.
Based on Goldman Sachs's 13F filing for Q4 2020, filed 12 Feb 2021.